Showing 1031-1040 of 8790 results for "".
Jonathan Weiss, MD, Talks Acne Products with Benzoyl Peroxide (BPO) and How He's Advising Patients after Valisure's FDA Citizen's Petition
https://practicaldermatology.com/topics/acne-rosacea/jonathan-weiss-md-talks-acne-products-benzoyl-peroxide-bpo-and-how-hes-advising-patients-after-valisures-fda-citizens-petition/24170/Jonathan Weiss, MD, a dermatologist from Atlanta, says that at this point, "we just don’t know enough." He said he still feels comfortable prescribing these acne products with benzoyl peroxide (BPO) at the present time, and that more information is needed. His advice to fellow dermatologists is to uDermWireTV: Spevigo for GPP; Derms on Acne Experience; IFPA Takes PsO to the Gaming World; La Roche-Posay at the US Open
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spevigo-for-gpp-derms-on-acne-experience-ifpa-takes-pso-to-the-gaming-world-la-roche-posay-at-the-us-open/20136/Boehringer Ingelheim’s Spevigo is the first FDA-approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spesolimab is a novel, selective antibody that blocks the activation of the interleukin-36 receptor. Dermatologists, dermatology physician assistants, and dermatologyPsoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.DermWireTV: Birch Triterpenes Gel Gets FDA Approval for EB, VTE Risk is Lower in Patients with AD, and Are Topical Steroids Affecting Bone Health?
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-birch-triterpenes-t-gel-gets-fda-approval-for-eb-vte-risk-is-lower-in-patients-with-ad-and-are-topical-steroids-affecting-bone-health/20233/A birch bark extract topical from Chiesi Global Rare Diseases represents the latest in treatment approvals for epidermolysis bullosa. Patients with atopic dermatitis may have a decreased risk for developing venous thromboembolism. Commonly prescribed topical steroids may raise some patients' risk foDermWireTV: Atopic Dermatitis Pipeline Watch, a Potential New Skin Cancer Treatment; Demystifying Itch, and the Premiere of PA Perspectives
https://practicaldermatology.com/topics/practice-management/dermwiretv-atopic-dermatitis-pipeline-watch-a-potential-new-skin-cancer-treatment-demystifying-itch-and-the-premiere-of-pa-perspectives/20228/Escient Pharmaceuticals, Rapt Therapeutics, and Connect Biopharma each report positive results from early clinical studies in AD. Finnish researchers discover a potential treatment for cutaneous squamous cell carcinoma in an existing chemotherapy drug. Research out of Harvard Medical School links ecDermWireTV: Arcutis Survey on PsO Impact; Tinted Sunscreen Update; Cosmetic Interventions and Illness; Dr. Seemal Desai Elected
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-arcutis-survey-on-pso-impact-tinted-sunscreen-update-cosmetic-interventions-and-illness-dr-seema-desai-elected/20089/Arcutis Biotherapeutics' survey finds Individuals with psoriasis who use topical treatments want more effective and simpler interventions. Intertriginous disease poses particular challenges. Increased availability of tinted sunscreens could increase the use of SPF among individuals with darker skinDermWireTV: AbbVie's Science of Skin Panel, Monkeypox Warning, Recommendations on Skin Cancer Detection Devices, UV Filters and Aquatic Life
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-abbvies-science-of-skin-panel-monkeypox-warning-recommendations-on-skin-cancer-detection-devices-uv-filters-and-aquatic-life/20131/“The Science of Skin: United Beyond the Surface” program sponsored by AbbVie brings together leading dermatologists and patients or caregivers of patients with dermatologic disease to explore the burden of skin diseases on diverse populations and the need for optimized treatment approaches. Seemal DDermWire TV: Positive Data on UCB's Bimekizumab in HS patients; CSF takes Nashville by Storm; Rocatinlimab Performs Well in AD
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-positive-data-on-ucbs-bimekizumab-hs-patients-csf-takes-nashville-by-storm-rocatinlimab-performs-well-in-ad/20159/Bimekizumab performs well in Hidradenitis Suppurativa patients, Cosmetic Surgery Forum takes Nashville by storm, and Rocatinlimab—a novel monoclonal antibody therapy—shows promise in atopic dermatitis are the stories topping the news in this episode of DermWireTV.Part 2, 1726 nm lasers: All about the AviClear and Accure devices from clinical trial to today, including pulsing protocols and pain control methods
https://practicaldermatology.com/series/scientifically-speaking/1726-nm-lasers-five-dermatologists-discuss-the-lasers-benefits-and-drawbacks-for-treating-acne-and-other-skin-conditions/24340/Chapter 2 of 7: David Goldberg, MD, from New York, Emil Tanghetti, MD, from Sacramento, Jordan Wang, MD, from Philadelphia and New York and Naz Saedi, MD, from Philadelphia talk about the AviClear and Accure devices from clinical trial to today, including pulsing protocols and pain control methods.DermWire TV: Factors Affecting Long-term Antibiotic Prescriptions for Acne; Biologics Firm Focusing on Plaque Psoriasis Makes an Important Acquisition; Practical Dermatology Launches Two New Video Series
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-factors-affecting-long-term-antibiotic-prescriptions-acne-biologics-firm-focusing-plaque-psoriasis-makes-important-acquisition-practical-dermatology-launches-two-new-video-series/24319/In this episode of DermWire TV, a new analysis highlights factors affecting long-term antibiotic prescriptions for acne; a company developing plaque psoriasis biologics makes a major acquisition; and Practical Dermatology® launches two new video series focusing on advancing treatment and improving u